PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16430721-3	2006	We investigated whether renal as well as haemodynamic effects of losartan are associated with changes in the IGF-I system in normotensive patients with type 2 diabetes mellitus (T2DM).	Losartan	65-73	insulin like growth factor 1	Homo sapiens	109-114	
16868143-11	2006	CONCLUSIONS: Losartan raised serum levels of free IGF-I, which might contribute to the improvement of insulin resistance associated with losartan treatment.	Losartan	13-21	insulin like growth factor 1	Homo sapiens	50-55	
16868143-11	2006	CONCLUSIONS: Losartan raised serum levels of free IGF-I, which might contribute to the improvement of insulin resistance associated with losartan treatment.	Losartan	137-145	insulin like growth factor 1	Homo sapiens	50-55	
16430721-8	2006	Losartan tended to reduce IGFBP-3 levels and to increase free IGF-I levels, although neither effect was statistically significant.	Losartan	0-8	insulin like growth factor 1	Homo sapiens	62-67	
16430721-9	2006	These effects were more pronounced in a subanalysis of 18 losartan-treated patients with stable metabolic parameters, with a decrease in IGFBP-3 from 133.2 to 122.6 nmol/l (P=0.006) and an increase in free IGF-I levels by 8% (ns).	Losartan	58-66	insulin like growth factor 1	Homo sapiens	206-211	
14976148-6	2004	Furthermore, this process was blocked by losartan and 1-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP-1), indicating stimulation of IGF-I receptor phosphorylation occurs via AngII type 1 receptor-dependent activation of Src kinase.	Losartan	41-49	insulin like growth factor 1	Homo sapiens	165-170